Evofem makes top-to-bottom cuts to save cash, slashing CEO pay by 40% and eliminating positions

Evofem Biosciences is making top-to-bottom cuts in a bid to slash its costs. Months after laying off 39 people, the women’s health biotech has pushed more employees, including its chief commercial officer, out the door and cut the salary of its CEO by 40%.